Ab00511-10.7 Anti-Vaginolysin [9B4]
Description: Recombinant monoclonal antibody to Vaginolysin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 9B4. This antibody is in our proprietary AbFab2™ recombinant F(ab2) format - based on Human IgG1 sequence with a short dimerization domain to improve stability and a his tag.
Clone Number: 9B4
UniProt Accession Number of Target Protein:
Alternative Name(s) of Target: VLY
Published Application(s): ELISA; WB; Block
Published Species Reactivity: G. vaginalis
Immunogen: Recombinant VLY.
Specificity: The antibody binds to VLY with an affinity (Kd) of 0.29 nM and an IC50 of 0.067 nM (determined by hemolytic assay). The antibody has a strong neutralizing capability.
Application Notes: The antibody binds specifically to VLY, a pore-forming toxic member of the cholesterol-dependent cytolysins, produced by the bacterium Gardnerella vaginalis. Once released, VLY acts by binding to cholesterol-rich membranes and forming transmembrane pores that result in lysis of the cell. The bacterium G. vaginalis is predominant in the vaginal tract of women with bacterial vaginosis (BV). Here releases VLY toxins that cause cytolysis and tissue destruction, and potentially leading to serious adverse effects such as infertility. Antibodies that are able to neutralize the toxic activity of VLY can be used as therapeutic agents for the treatment of BV. The antibody 9B4 has the strongest neutralizing activity, and binds to an epitope region comprising of the amino acids 122 to 268 of VLY.
Antibody First Published in:
Zvirbliene A, Pleckaityte M, Lasickiene R, Kucinskaite-Kodze I, Zvirblis G. Production and characterization of monoclonal antibodies against vaginolysin: mapping of a region critical for its cytolytic activity. Toxicon. 2010 Aug 1;56(1):19-28. PMID:20298711 Note on publication: Describes the generation of two monoclonal antibodies with neutralizing activity against vaginolysin, the causative agent of bacterial vaginosis.
Concentration: See vial label.
This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Species and Isotype: Human F(ab)2, AbFab2™ His-Tagged, kappaClone Number: 9B4
UniProt Accession Number of Target Protein:
Alternative Name(s) of Target: VLY
Published Application(s): ELISA; WB; Block
Published Species Reactivity: G. vaginalis
Immunogen: Recombinant VLY.
Specificity: The antibody binds to VLY with an affinity (Kd) of 0.29 nM and an IC50 of 0.067 nM (determined by hemolytic assay). The antibody has a strong neutralizing capability.
Application Notes: The antibody binds specifically to VLY, a pore-forming toxic member of the cholesterol-dependent cytolysins, produced by the bacterium Gardnerella vaginalis. Once released, VLY acts by binding to cholesterol-rich membranes and forming transmembrane pores that result in lysis of the cell. The bacterium G. vaginalis is predominant in the vaginal tract of women with bacterial vaginosis (BV). Here releases VLY toxins that cause cytolysis and tissue destruction, and potentially leading to serious adverse effects such as infertility. Antibodies that are able to neutralize the toxic activity of VLY can be used as therapeutic agents for the treatment of BV. The antibody 9B4 has the strongest neutralizing activity, and binds to an epitope region comprising of the amino acids 122 to 268 of VLY.
Antibody First Published in:
Zvirbliene A, Pleckaityte M, Lasickiene R, Kucinskaite-Kodze I, Zvirblis G. Production and characterization of monoclonal antibodies against vaginolysin: mapping of a region critical for its cytolytic activity. Toxicon. 2010 Aug 1;56(1):19-28. PMID:20298711 Note on publication: Describes the generation of two monoclonal antibodies with neutralizing activity against vaginolysin, the causative agent of bacterial vaginosis.
Product Form
Purification: Purified by Immobilized Metal Affinity Chromatography Supplied in: Bulk size: PBS only. Standard size: PBS with 0.02% Proclin 300.
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°CConcentration: See vial label.
Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic
procedures for humans or animals.
2650
